请输入您要查询的百科知识：

　

词条 Omeprazole
释义

  1. Medical uses

     Peptic ulcers 

  2. Adverse effects

     Pregnancy and breast-feeding 

  3. Interactions

  4. Pharmacology

     Mechanism of action  Pharmacokinetics 

  5. Chemistry

     Measurement in body fluids 

  6. History

  7. Society and culture

     Dosage forms  Brand names 

  8. References

  9. External links

{{short description|proton-pump inhibitor}}{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462265342
| drug_name =
| IUPAC_name = 5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-benzimidazole
| image = Omeprazole.svg
| chirality = Racemic mixture
| width = 200
| image2 = Omeprazole-3D-balls.png
| width2 = 200
| pronounce = {{IPAc-en|oʊ|ˈ|m|ɛ|p|r|ə|z|oʊ|l}}
| tradename = Losec, Prilosec, Zegerid, others[1]
| Drugs.com = {{drugs.com|monograph|omeprazole}}
| class = Proton-pump inhibitor
| pregnancy_US = C
| pregnancy_AU = B3
| legal_AU = S4
| legal_UK = gsl
| legal_US = OTC
| routes_of_administration= by mouth, IV
| licence_US = Omeprazole
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KG60484QX9
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00455
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1503
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SUBDBMMJDZJVOS-UHFFFAOYSA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number=73590-58-6
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4433
| ATC_prefix=A02
| ATC_suffix=BC01
| ATC_supplemental=
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 7772
| IUPHAR_ligand = 4279
| PubChem=4594
| PDB_ligand = 1C6
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00338
| C=17 | H=19 | N=3 | O=3 | S=1
| molecular_weight = 345.42 g/mol
| smiles = COc3ccc2[nH]c(S(=O)Cc1ncc(C)c(OC)c1C)nc2c3
| bioavailability= 35–76%[1][2]
| protein_bound = 95%
| metabolism = Hepatic (CYP2C19, CYP3A4)
| elimination_half-life= 1–1.2 hours
| excretion = 80% (urine)
20% (feces)
|melting_point = 156
|alt=|caption=|type=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_category=|density=1.4±0.1 [3]
}}Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome.[4] It is also used to prevent upper gastrointestinal bleeding in people who are at high risk.[4] Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to other PPIs.[5] It can be taken by mouth or by injection into a vein.[4][6]

Common side effects include nausea, vomiting, headaches, and increased intestinal gas.[4] Serious side effects may include Clostridium difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer.[4] It is unclear if it is safe for use in pregnancy.[4] It works by blocking the release of stomach acid.[4]

Omeprazole was patented in 1978 and approved for medical use in 1988.[7] It is on the World Health Organization's List of Essential Medicines, which lists the most effective and safe medicines needed in a health system.[8] It is available as a generic medication.[4] The wholesale cost in the developing world as of 2014 is US$0.01 to US$0.07 per dose.[9] In the United States, it costs on average US$0.50 per pill.[10] In 2016, it was the seventh most prescribed medication in the United States, with more than 70 million prescriptions.[11]

Medical uses

{{See also|Proton-pump inhibitor}}

Omeprazole can be used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, Zollinger-Ellison syndrome, and eosinophilic esophagitis.[12][4]

Peptic ulcers

Peptic ulcers may be treated with omeprazole. Treatment of a Helicobacter pylori infection can be completed by taking a triple therapy combination of omeprazole, amoxicillin, and clarithromycin for 7–14 days.[13] Amoxicillin may be replaced with metronidazole in patients who are allergic to penicillin.[14]

Adverse effects

The most frequent significant adverse effects occurring in at least 1% of patients include:[15]

  • Central nervous system: headache (7%), dizziness (2%)
  • Respiratory: upper respiratory tract infection (2%), cough (1%)
  • Gastrointestinal: abdominal pain (5%), diarrhea (4%), nausea (4%), vomiting (3%), flatulence (3%), acid regurgitation (2%), constipation (2%)
  • Neuromuscular and skeletal: back pain (1%), weakness (1%)
  • Dermatologic: rash (2%)

Other concerns related to adverse effects are:

  • Recurrence of Clostridium difficile associated diarrhea[16]
  • Osteoporosis-related fractures[17][18]
  • Hypomagnesemia[19]

Concern has been expressed regarding vitamin B12[20] and iron malabsorption,[21] but effects seem to be insignificant, especially when supplement therapy is provided.[22]

Since their introduction, proton-pump inhibitors (PPIs, especially omeprazole) have also been associated with several cases of acute interstitial nephritis,[23] an inflammation of the kidneys that often occurs as an adverse drug reaction.

Long-term use of PPIs is strongly associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. No association is seen between PPI use and cancer, but use of PPIs may mask gastric cancers or other serious gastric problems and physicians should be aware of this effect.[24]

There is a tentative association between long term use and dementia which requires further study to confirm.[25]

Pregnancy and breast-feeding

Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.[26]

No clinical trials have deeply evaluated the potential consequences of the use of omeprazole in breastfeeding. However, the pharmacokinetics of the omeprazole molecule strongly suggest the safety of omeprazole use during breastfeeding:

  • Omeprazole has a high plasma protein binding rate (95%),[27] indicating that little amount of drug is transferred to the milk duct during breast milk formation.
  • Omeprazole needs to be administrated in an enteric-coated formulation due to its rapid degradation in the acidic conditions of the stomach. This suggests that most of the free molecules ingested by the infant are likely degraded before being absorbed.{{citation needed|date=March 2016}}

Omeprazole at normal doses is likely safe during breastfeeding.[28]

Interactions

Important drug interactions are rare.[29][30] However, the most significant major drug interaction concern is the decreased activation of clopidogrel when taken together with omeprazole.[31] Although still controversial,[32] this may increase the risk of stroke or heart attack in people taking clopidogrel to prevent these events.

This interaction is possible because omeprazole is an inhibitor of the enzymes CYP2C19 and CYP3A4.[33] Clopidogrel is an inactive prodrug that partially depends on CYP2C19 for conversion to its active form. Inhibition of CYP2C19 may block the activation of clopidogrel, which could reduce its effects.[34][35]

Almost all benzodiazepines are metabolised by the CYP3A4 and CYP2D6 pathways, and inhibition of these enzymes results in a higher AUC (i.e., the total effect over time of a given dose). Other examples of drugs dependent on CYP3A4 for their metabolism are escitalopram,[36] warfarin,[37] oxycodone, tramadol, and oxymorphone. The concentrations of these drugs may increase if they are used concomitantly with omeprazole.[38]

Omeprazole is also a competitive inhibitor of p-glycoprotein, as are other PPIs.[39]

Drugs that depend on an acidic stomach environment (such as ketoconazole or atazanavir) may be poorly absorbed, whereas acid-labile antibiotics (such as erythromycin which is a very strong CYP3A4 inhibitor) may be absorbed to a greater extent than normal due to the more alkaline environment of the stomach.[38]

St. John's wort (Hypericum perforatum) and Gingko biloba significantly reduce plasma concentrations of omeprazole through induction of CYP3A4 and CYP2C19.[40]

Proton-pump inhibitors like omeprazole have been found to increase the plasma concentrations of methotrexate.[41]

Pharmacology

Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for secretion of gastric acid. It is a specific H+/K+ATPase inhibitor. This is the enzyme needed for the final step in secretion of gastric acid.[42]

Mechanism of action

Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H+/K+-ATPase system found at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as the acid (proton, or H+) pump within the gastric mucosa, omeprazole inhibits the final step of acid production.[42]

Omeprazole also inhibits both basal and stimulated acid secretion irrespective of the stimulus[54] as it blocks the last step in acid secretion.[54] The drug binds non-competitively so has a dose dependent effect.[43]

The inhibitory effect of omeprazole occurs within 1 hour after oral administration. The maximum effect occurs within 2 hours. The duration of inhibition is up to 72 hours. When omeprazole is stopped, baseline stomach acid secretory activity returns after 3 to 5 days. The inhibitory effect of omeprazole on acid secretion will plateau after 4 days of repeated daily dosing.[44]

Pharmacokinetics

The absorption of omeprazole takes place in the small intestine and is usually completed within 3 to 6 hours. The systemic bioavailability of omeprazole after repeated doses is about 60%.[45] Omeprazole has a volume of distribution of 0.4 L/kg. It has high plasma protein binding of 95%. [46]

Omeprazole, as well as other PPIs, are only effective on active H+/K+-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion. For this reason, patients should be advised to take omeprazole with a glass of water on an empty stomach.[47] Additionally, most sources recommend that after taking omeprazole, at least 30 minutes should be allowed to elapse before eating[48][49] (at least 60 minutes for immediate-release omeprazole plus sodium bicarbonate products, such as Zegerid),[50] though some sources say that with delayed-release forms of omeprazole, waiting before eating after taking the medication is not necessary.[51]

Omeprazole is completely metabolized by the cytochrome P450 system, mainly in the liver. Identified metabolites are the sulfone, the sulfide, and hydroxy-omeprazole, which exert no significant effect on acid secretion. About 77% of an orally given dose is excreted as metabolites in the urine, and the remainder is found in the feces, primarily originating from bile secretion.[54] Omeprazole has a half life of 0.5 to 1 hour.[52] The pharmacological effects of omeprazole last longer as it is covalently bonded to proton pump on parietal cells to induce effects.

Chemistry

Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and therefore can exist as either the (S)- or (R)-enantiomers. Omeprazole is a racemate, an equal mixture of the two. In the acidic conditions of the canaliculi of parietal cells, both enantiomers are converted to chiral products (sulfenic acid and sulfenamide configurations) which react with a cysteine group in H+/K+ ATPase, thereby inhibiting the ability of the parietal cells to produce gastric acid.{{citation needed|date=March 2016}}

AstraZeneca has also developed esomeprazole (Nexium) which is a eutomer, purely the (S)-enantiomer, rather than a racemate like omeprazole.

Omeprazole undergoes a chiral shift in vivo which converts the inactive (R)-enantiomer to the active (S)-enantiomer, doubling the concentration of the active form.[53] This chiral shift is accomplished by the CYP2C19 isozyme of cytochrome P450, which is not found equally in all human populations. Those who do not metabolize the drug effectively are called "poor metabolizers". The proportion of the poor metabolizer phenotype varies widely between populations, from 2.0–2.5% in African Americans and white Americans to >20% in Asians. Several pharmacogenomics studies have suggested that PPI treatment should be tailored according to CYP2C19 metabolism status.[54]

Measurement in body fluids

Omeprazole may be quantified in plasma or serum to monitor therapy or to confirm a diagnosis of poisoning in hospitalized patients. Plasma omeprazole concentrations are usually in a range of 0.2–1.2 mg/l in persons receiving the drug therapeutically by the oral route and 1–6 mg/l in victims of acute overdose. Enantiomeric chromatographic methods are available to distinguish esomeprazole from racemic omeprazole.[55]

History

{{main|Discovery and development of proton pump inhibitors }}

Omeprazole was first marketed in the United States in 1989 by Astra AB, now AstraZeneca, under the brand name Losec. In 1990, at the request of the U.S. Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide).[56] The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant.[56]

When Prilosec's U.S. patent expired in April 2001, AstraZeneca introduced esomeprazole (Nexium) as a patented replacement drug.[57] Many companies introduced generics as AstraZeneca's patents expired worldwide, which are available under many brand names.

Society and culture

Dosage forms

Omeprazole is available as tablets and capsules (containing omeprazole or omeprazole magnesium) in strengths of 10, 20, 40, and in some markets 80 mg; and as a powder (omeprazole sodium) for intravenous injection. Most oral omeprazole preparations are enteric-coated, due to the rapid degradation of the drug in the acidic conditions of the stomach. This is most commonly achieved by formulating enteric-coated granules within capsules, enteric-coated tablets, and the multiple-unit pellet system (MUPS).[58] An immediate release formulation was approved by the FDA in the United States,[59] which does not require enteric coating.

It is also available for use in injectable form (IV) in Europe, but not in the U.S. The injection pack is a combination pack consisting of a vial and a separate ampule of reconstituting solution. Each 10-mL clear glass vial contains a white to off-white lyophilised powder consisting of omeprazole sodium 42.6 mg, equivalent to 40 mg of omeprazole.

Omeprazole is also available as an oral suspension of enteric-coated beads in the UK as an unlicensed product. Oral suspensions are predominantly used for children, but can also be used by those with difficulty swallowing or those using a feeding tube.

Brand names

Brand names include Losec, Prilosec, Zegerid, Miracid, among others.[60][4]

References

1. ^{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf |title=Prilosec Prescribing Information |date=September 2012 |access-date=October 21, 2018 |publisher=AstraZeneca Pharmaceuticals}}
2. ^{{cite journal |last1=Vaz-Da-Silva |first1=Manuel |last2=Loureiro |first2=Ana I. |last3=Nunes |first3=Teresa |last4=Maia |first4=Joana |last5=Tavares |first5=Susana |last6=Falcão |first6=Amilcar |last7=Silveira |first7=Pedro |last8=Almeida |first8=Luis |last9=Soares-Da-Silva |first9=Patricio |title=Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions |journal=Clinical Drug Investigation |volume=25 |issue=6 |pages=391–399 |year=2005 |pmid=17532679 |url=http://www.medscape.com/viewarticle/508018 |doi=10.2165/00044011-200525060-00004 |dead-url=no |archive-url=https://web.archive.org/web/20130313204630/http://www.medscape.com/viewarticle/508018 |archive-date=March 13, 2013 |access-date=October 21, 2018}}
3. ^{{cite web |url=https://www.chemsrc.com/en/cas/73590-58-6_591579.html |title=Omeprazole MSDS |access-date=October 21, 2018}}
4. ^1 2 3 4 5 6 7 8 9 10 {{cite web |title=Omeprazole |url=https://www.drugs.com/monograph/omeprazole.html |publisher=The American Society of Health-System Pharmacists |access-date=October 21, 2018}}
5. ^{{cite web|title=[99] Comparative effectiveness of proton pump inhibitors {{!}} Therapeutics Initiative|url=http://www.ti.ubc.ca/2016/06/28/99-comparative-effectiveness-proton-pump-inhibitors/|accessdate=14 July 2016|date=28 June 2016}}
6. ^{{cite web |title=Omeprazole 40 mg Powder for Solution for Infusion |url=https://www.medicines.org.uk/emc/medicine/25259 |website=EMC |access-date=October 21, 2018 |date=February 10, 2016 |dead-url=no |archive-url=https://web.archive.org/web/20160407193540/https://www.medicines.org.uk/emc/medicine/25259 |archive-date=April 7, 2016}}
7. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=445 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA445 |language=en}}
8. ^{{cite web |title=WHO Model List of Essential Medicines (19th List) |url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 |work=World Health Organization |access-date=October 21, 2018 |date=April 21, 2015 |dead-url=no |archive-date=December 13, 2016 |archive-url=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1}}
9. ^{{cite web |title=Omeprazole |url=http://mshpriceguide.org/en/single-drug-information/?DMFId=571&searchYear=2014 |website=International Drug Price Indicator Guide |access-date=October 21, 2018 |dead-url=no |archive-url=https://web.archive.org/web/20170510100736/http://mshpriceguide.org/en/single-drug-information/?DMFId=571&searchYear=2014 |archive-date=May 10, 2017}}
10. ^{{cite web |title=NADAC as of 2016-11-16 Data.Medicaid.gov |url=https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-16/dyki-3gk4 |publisher=Centers for Medicare and Medicaid Services |dead-url=no |archive-url=https://web.archive.org/web/20161117144955/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-16/dyki-3gk4 |archive-date=November 17, 2016 |access-date=October 21, 2018}}
11. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}}
12. ^{{cite journal |last=Cheng |first=Edaire |date=July 21, 2013 |title=Proton Pump Inhibitors for Eosinophilic Esophagitis |journal=Current Opinion in Gastroenterology |volume=29 |issue=4 |pages=416–420 |doi=10.1097/MOG.0b013e32835fb50e |issn=0267-1379 |pmc=4118554 |pmid=23449027 }}
13. ^{{cite journal |pmid=17938394 |year=2007 |last1=Fuccio |first1=Lorenzo |title=Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication |journal=Annals of Internal Medicine |volume=147 |issue=8 |pages=553–62 |last2=Minardi |first2=Maria Eugenia |last3=Zagari |first3=Rocco Maurizo |last4=Grilli |first4=Diego |last5=Magrini |first5=Nicola |last6=Bazzoli |first6=Franco |doi=10.7326/0003-4819-147-8-200710160-00008}}
14. ^{{cite journal |vauthors=Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ |title=Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report |journal=Gut |volume=56 |issue=6 |pages=772–81 |date=June 21, 2007 |pmid=17170018 |pmc=1954853 |doi=10.1136/gut.2006.101634 |subscription=yes }}
15. ^{{cite journal |vauthors=McTavish D, Buckley MM, Heel RC |title=Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders |journal=Drugs |volume=42 |issue=1 |pages=138–70 |pmid=1718683 |year=1991 |doi=10.2165/00003495-199142010-00008}}
16. ^{{cite journal |last1=Abou Chakra |first1=CN |display-authors=etal |date=June 21, 2014 |title=Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review |journal=PLoS ONE |volume=9 |issue=6 |page=e98400 |doi=10.1371/journal.pone.0098400 |pmid=24897375 |pmc=4045753 |bibcode=2014PLoSO...998400A}}
17. ^{{cite journal |last1=Yang |first1=Yu-Xiao |display-authors=etal |year=2006 |title=Long-term proton pump inhibitor therapy and risk of hip fracture |journal=JAMA |volume=296 |issue=24 |pages=2947–2953 |doi=10.1001/jama.296.24.2947 |pmid=17190895}}
18. ^{{cite journal |last1=Yu |first1=Elaine W. |display-authors=etal |year=2011 |title=Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies |journal=The American Journal of Medicine |volume=124 |issue=6 |pages=519–526 |doi=10.1016/j.amjmed.2011.01.007 |pmid=21605729 |pmc=3101476}}
19. ^{{cite journal |last1=Hess |first1=M. W. |display-authors=etal |year=2012 |title=Systematic review: hypomagnesaemia induced by proton pump inhibition |journal=Alimentary Pharmacology & Therapeutics |volume=36 |issue=5 |pages=405–413 |doi=10.1111/j.1365-2036.2012.05201.x|pmid=22762246 }}
20. ^{{cite journal |last1=Neal |first1=Keith |last2=Logan |first2=Richard |year=2001 |title=Potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors |journal=Alimentary Pharmacology & Therapeutics |volume=15 |issue=7 |pages=1085–6 |pmid=11421886 |doi=10.1046/j.1365-2036.2001.0994a.x}}
21. ^{{cite journal |last1=Sarzynski |first1=Erin |display-authors=etal |year=2011 |title=Association between proton pump inhibitor use and anemia: a retrospective cohort study |journal=Digestive Diseases and Sciences |volume=56 |issue=8 |pages=2349–2353 |doi=10.1007/s10620-011-1589-y |pmid=21318590}}
22. ^{{cite journal |last1=McColl |first1=Kenneth EL |year=2009 |title=Effect of proton pump inhibitors on vitamins and iron |journal=The American Journal of Gastroenterology |volume=104 |pages=S5–S9 |doi=10.1038/ajg.2009.45 |pmid=19262546}}
23. ^{{cite journal |last1=Härmark |first1=Linda |display-authors=et al |year=2007 |title=Proton pump inhibitor‐induced acute interstitial nephritis |journal=British Journal of Clinical Pharmacology |volume=64 |issue=6 |pages=819–823 |doi=10.1111/j.1365-2125.2007.02927.x |pmid=17635502 |pmc=2198775}}
24. ^{{cite journal |author=Corleto, V.D. |title=Proton pump inhibitor therapy and potential long-term harm. |journal=Curr Opin Endocrinol Diabetes Obes |date=February 21, 2014 |volume=21 |issue=1 |pages=3–8 |pmid=24310148 |doi=10.1097/med.0000000000000031}}
25. ^{{cite journal |last1=Eusebi |first1=LH |last2=Rabitti |first2=S |last3=Artesiani |first3=ML |last4=Gelli |first4=D |last5=Montagnani |first5=M |last6=Zagari |first6=RM |last7=Bazzoli |first7=F |title=Proton pump inhibitors: Risks of long-term use. |journal=Journal of Gastroenterology and Hepatology |date=July 21, 2017 |volume=32 |issue=7 |pages=1295–1302 |doi=10.1111/jgh.13737 |pmid=28092694}}
26. ^{{cite journal |doi=10.1056/NEJMoa1002689 |pmid=21105793 |title=Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects |journal=New England Journal of Medicine |volume=363 |issue=22 |pages=2114–23 |year=2010 |last1=Pasternak |first1=Björn |last2=Hviid |first2=Anders}}
27. ^{{cite web |url=http://www.pdr.net/drug-summary/prilosec-delayed-release-capsules-and-oral-suspension?druglabelid=1123 |title=Omeprazole drug summary |publisher=PDR.net |access-date=October 21, 2018 |dead-url=no |archive-url=https://web.archive.org/web/20140303163837/http://www.pdr.net/drug-summary/prilosec-delayed-release-capsules-and-oral-suspension?druglabelid=1123 |archive-date=March 3, 2014}}
28. ^{{cite web |title=LACTMED: OMEPRAZOLE |url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@rel+@rn+73590-58-6 |access-date=October 21, 2018 |date=March 10, 2015 |dead-url=no |archive-url=https://web.archive.org/web/20170908170635/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed%253A%2540term+%2540rel+%2540rn+73590-58-6 |archive-date=September 8, 2017}}
29. ^{{cite web |last=Fitzakerley |first=Janet |url=http://www.d.umn.edu/~jfitzake/Lectures/DMED/Antiulcer/Treatment/ReducePain/PPIs/PPIsSE.html |title=2014 Treatments for Acid-Peptic Diseases. |access-date=October 21, 2018|dead-url=yes | archive-url=https://web.archive.org/web/20140419014436/http://www.d.umn.edu/~jfitzake/Lectures/DMED/Antiulcer/Treatment/ReducePain/PPIs/PPIsSE.html |archive-date=April 19, 2014 |publisher=University of Minnesota Medical School Duluth}}
30. ^{{cite web |url=http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ppi-adult-factsheet.pdf |title=Proton Pump Inhibitor: Use in Adults |archive-url=https://web.archive.org/web/20131212143828/http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ppi-adult-factsheet.pdf |archive-date=December 12, 2013 |access-date=October 21, 2018 |work=CMS Medicaid Integrity Program}}
31. ^{{cite journal |pmc=3392956 |title=Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs |journal=BMJ |volume=345 |pages=e4388 |year=2012 |author1=Douglas |first1=I. J. |last2=Evans |first2=S. J. |last3=Hingorani |first3=A. D. |last4=Grosso |first4=A. M. |last5=Timmis |first5=A |last6=Hemingway |first6=H| last7=Smeeth |first7=L |doi=10.1136/bmj.e4388 |pmid=22782731}}
32. ^{{cite journal |doi=10.1136/heartjnl-2012-302371 |pmid=22851683 |title=Concomitant use of clopidogrel and proton pump inhibitors: Impact on platelet function and clinical outcome- a systematic review |journal=Heart |volume=99 |issue=8 |pages=520–7 |year=2012 |last1=Focks |first1=J. J. |last2=Brouwer |first2=M. A. |last3=Van Oijen |first3=M. G. H. |last4=Lanas |first4=A. |last5=Bhatt |first5=D. L. |last6=Verheugt |first6=F. W. A.}}
33. ^{{Cite journal |pmid=23620487 |title= Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions |date= July 2013 |doi=10.1124/dmd.113.051722 |pmc=3684819 |volume=41 |issue=7 |journal=Drug Metab. Dispos. |pages=1414–24 |author1=Shirasaka |first1=Y |last2=Sager |first2=J. E. |last3=Lutz |first3=J. D. |last4=Davis |first4=C |last5=Isoherranen |first5=N }}
34. ^{{cite journal |vauthors=Lau WC, Gurbel PA |title=The drug-drug interaction between proton pump inhibitors and clopidogrel |journal=CMAJ |volume=180 |issue=7 |pages=699–700 |date=March 2009 |pmid=19332744 |pmc=2659824 |doi=10.1503/cmaj.090251}}
35. ^{{cite journal |vauthors=Norgard NB, Mathews KD, Wall GC |title=Drug-drug interaction between clopidogrel and the proton pump inhibitors |journal=Ann Pharmacother |volume=43 |issue=7 |pages=1266–1274 |date=July 2009 |pmid=19470853 |doi=10.1345/aph.1M051}}
36. ^{{EMedicine|article|1879354|Selective Serotonin Reuptake Inhibitors and CYP2D6}}
37. ^{{cite journal |vauthors=Daly AK, King BP | title = Pharmacogenetics of oral anticoagulants | journal = Pharmacogenetics | volume = 13 | issue = 5 | pages = 247–52 |date=May 2003 | pmid = 12724615 | doi = 10.1097/00008571-200305000-00002}}
38. ^1 {{cite journal |vauthors=Stedman CA, Barclay ML |title=Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors |journal=Aliment Pharmacol Ther |volume=14 |issue=8 |pages=963–978 |date=August 2000 |pmid=10930890 |doi=10.1046/j.1365-2036.2000.00788.x}}
39. ^{{cite journal |vauthors=Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF |title=Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein |journal=Naunyn Schmiedebergs Arch Pharmacol |volume=364 |issue=6 |pages=551–557 |date=December 2001 |pmid=11770010 |doi=10.1007/s00210-001-0489-7}}
40. ^{{cite journal | last1 = Izzo | first1 = AA | last2 = Ernst | first2 = E | title = Interactions between herbal medicines and prescribed drugs: an updated systematic review | journal = Drugs | volume = 69 | issue = 13 | pages = 1777–1798 | year = 2009 | pmid = 19719333 | doi=10.2165/11317010-000000000-00000 }}
41. ^{{cite web |title=Methotrexate |work=Martindale: The Complete Drug Reference |publisher=Pharmaceutical Press |date=6 January 2014 |accessdate=12 April 2014 |url= http://www.medicinescomplete.com/mc/martindale/current/ms-9550-n.htm |editor=Brayfield, A}}
42. ^1 {{cite journal |last1=Howden |first1=CW |title=Clinical pharmacology of omeprazole. |journal=Clinical Pharmacokinetics |date=January 1991 |volume=20 |issue=1 |pages=38–49 |doi=10.2165/00003088-199120010-00003 |pmid=2029801 }}
43. ^{{cite journal |last1=Clissold |first1=Stephen P. |last2=Campoli-Richards |first2=Deborah M. |title=Omeprazole |journal=Drugs |date=July 1986 |volume=32 |issue=1 |pages=15–47 |doi=10.2165/00003495-198632010-00002 |pmid=3527658 }}
44. ^Omeprazole [package insert]. {{webarchive|url=https://web.archive.org/web/20140419020303/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bced816b-6927-49fb-851f-f83a678dac97 |date=19 April 2014 }} India: Dr. Reddy's Laboratories Limited. Revised: 0613
45. ^{{Cite journal|last=Cederberg|first=C.|last2=Andersson|first2=T.|last3=Skånberg|first3=I.|date=1989-01-01|title=Omeprazole: Pharmacokinetics and Metabolism in Man|url=https://doi.org/10.3109/00365528909091241|journal=Scandinavian Journal of Gastroenterology|volume=24|issue=sup166|pages=33–40|doi=10.3109/00365528909091241|issn=0036-5521}}
46. ^{{cite journal |last1=Clissold |first1=Stephen P. |last2=Campoli-Richards |first2=Deborah M. |title=Omeprazole |journal=Drugs |date=July 1986 |volume=32 |issue=1 |pages=15–47 |doi=10.2165/00003495-198632010-00002 |pmid=3527658 }}
47. ^{{cite journal | last1 = Katz | first1 = PO | last2 = Gerson | first2 = LB | last3 = Vela | first3 = MF | year = 2013 | title = Guidelines for the diagnosis and management of gastroesophageal reflux disease | url = | journal = Am J Gastroenterol | volume = 108 | issue = 3| pages = 308–28 | doi=10.1038/ajg.2012.444 | pmid=23419381}}
48. ^{{cite web|url=http://medical-dictionary.thefreedictionary.com/omeprazole|title=Omeprazole, in The Free Medical Dictionary|accessdate=11 November 2010 }}
49. ^{{cite web|url=https://www.drugs.com/monograph/omeprazole.html|title=Omeprazole|publisher=Drugs.com|accessdate=11 November 2010|deadurl=no|archiveurl=https://web.archive.org/web/20110219135631/http://www.drugs.com/monograph/omeprazole.html|archivedate=19 February 2011|df=dmy-all}}
50. ^{{cite web |url=http://www.rxlist.com/zegerid-drug-patient.htm#howtake |title=Zegird, How to take |publisher=rxlist.com |accessdate=11 November 2010 |deadurl=no |archiveurl=https://web.archive.org/web/20101026072806/http://www.rxlist.com/zegerid-drug-patient.htm#howtake |archivedate=26 October 2010 |df=dmy-all }}
51. ^essential drug information. MIMS USA. Retrieved 20 December 2009.{{verify source|date=January 2011}}
52. ^1 2 3 {{cite web |title=Omeprazole |url=https://www.drugbank.ca/drugs/DB00338 |website=www.drugbank.ca |accessdate=29 January 2019}}
53. ^Nexium Prescribing Information {{webarchive|url=https://web.archive.org/web/20091008000830/http://www1.astrazeneca-us.com/pi/Nexium.pdf |date=8 October 2009 }}. AstraZeneca Pharmaceuticals.
54. ^{{cite journal |vauthors=Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T | title = Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies | journal = Drug Metab Pharmacokinet | volume = 20 | issue = 3 | pages = 153–67 |date=Jun 2005 | pmid = 15988117 | doi = 10.2133/dmpk.20.153}}
55. ^Baselt RC, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1146–7. {{ISBN|978-0-9626523-7-0}}.
56. ^1 {{cite journal |last = Farley |first = D |title = Making it easier to read prescriptions |journal = FDA Consum |volume = 29 |issue = 6 |pages = 25–7 |date = July–August 1995 |pmid = 10143448 |url = http://www.thebody.com/content/art13913.html |deadurl = no |archiveurl = https://web.archive.org/web/20120315172345/http://www.thebody.com/content/art13913.html |archivedate = 15 March 2012 |df = dmy-all}}
57. ^{{cite news |title=Prilosec's Maker Switches Users To Nexium, Thwarting Generics |author=Gardiner Harris |work=The Wall Street Journal |url=https://www.wsj.com/articles/SB1023326369679910840 |date=6 June 2002 |deadurl=no |archiveurl=https://web.archive.org/web/20170806181248/https://www.wsj.com/articles/SB1023326369679910840 |archivedate=6 August 2017 |df=dmy-all }}
58. ^Jerome Aubert*, Chris JJ Mulder†, Karsten Schrör**, Stephan R Vavricka††. "Omeprazole MUPS®: An Advanced Formulation offering Flexibility and Predictability for Self Medication." {{webarchive|url=https://web.archive.org/web/20160611031526/http://selfcarejournal.com/article/omeprazole-mups-an-advanced-formulation-offering-flexibility-and-predictability-for-self-medication/ |date=11 June 2016 }} SelfCare Journal 2 (2011): 0-0.
59. ^Santarus. Santarus Receives FDA Approval for Immediate-Release Omeprazole Tablet with Dual Buffers. {{webarchive|url=https://archive.is/20140418220348/http://ir.santarus.com/common/mobile/iphone/releasedetail.cfm?ReleaseID=428404&CompanyID=SNTS&mobileid= |date=18 April 2014 }} N.p., 4 December 2009. Web. 18 April 2014.
60. ^{{cite web |title=Miracid |url=https://www.drugs.com/international/miracid.html |website=Drugs.com |accessdate=February 2, 2019 |language=en}}

External links

{{commons category}}
  • U.S. National Library of Medicine: Drug Information Portal – Omeprazole
  • [https://www.ncbi.nlm.nih.gov/books/NBK100895/ U.S. National Center for Biotechnology Information: Medical Genetics Summaries - Omeprazole Therapy and CYP2C19 Genotype]
{{Proton-Pump Inhibitors}}{{Xenobiotic-sensing receptor modulators}}{{AstraZeneca}}{{authority control}}{{Use dmy dates|date=January 2012}}{{portal bar|Pharmacy and pharmacology|Medicine}}

9 : AstraZeneca|Benzimidazoles|Equine medications|Phenol ethers|Proton pump inhibitors|Pyridines|Sulfoxides|World Health Organization essential medicines|RTT
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/21 22:23:18